Astellas Pharma Inc. and Seattle Genetics, Inc. were granted Breakthrough Therapy designation by the FDA for PADCEV (enfortumab vedotin-ejfv) in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) for the treatment of unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting. The FDA’s Breakthrough Therapy designation aims to expedite the development and review of drugs that are i...